Helix BioPharma Corporation
|
|
- Charlene Boyd
- 6 years ago
- Views:
Transcription
1 Helix BioPharma Corporation Tumor Defence Breaker Corporate Presentation National Investment Banking Association October 2016
2 Forward-looking Statements This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within the meaningofapplicable securities laws. Forward-lookingstatements are statements andinformationthat are not historical facts but insteadinclude financial projections and estimates; statements regarding plans, goals, objectives, intentions and expectations with respect to Helix s future business, operations, research and development, including the focus of Helix on its DOS drug candidate generally and L-DOS47 in particular, the anticipated timelines for the commencement or completion of certain activities,including enrolment of patients in Helix s Phase I/II clinical trial for L-DOS47 in Poland, the expansion of the DOS47 platform into other compounds and indications and other information in future periods. Forward-looking statements, which may be identified by words including, without limitation, expects, plans, will, intends, may, pending, objective, exploring, potential, projected, possible and other similar expressions, are intended to provide informationaboutmanagement s currentplans andexpectations regarding future operations. Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation: (i) the inherent uncertainty involved in scientific research and drug development, including with respect to costs and difficulties in predicting accurate timelines for the commencement or completion of certain activities; (ii) the risks associated with delay or inability to complete clinical trials successfully and the long lead-times and high costs associated with obtaining regulatory approval to market any product which may result from successful completion of such trials; (iii) the need to secure additional financing on terms satisfactory to Helix or at all, including that the additional funding required in order to complete the proposed U.S. Phase I clinical trial will be obtained on terms satisfactory to Helix or at all; (iv) clinical trials that yield negative results, or results that do not justify future clinical development, including that Helix s ongoing Polish Phase I/II clinical trial for L-DOS47 and/or that Helix s proposed U.S. Phase I clinical trial will yield negative results; (v) Helix s clinical development plan for the proposed US Phase I clinical trial not proceeding in the manner or on the timelines anticipated by Helix or at all; and (vi) those risks and uncertainties affecting Helix as more fully described in Helix s most recent Annual Information Form, including under the headings Forward-Looking Statements and Risk Factors, filed under Helix s profile on SEDAR at (together, the Helix Risk Factors ). Certain material factors and assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix s actual results or events to differ materiallyfrom the forward-looking statements. Helix. Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix s management on the date of this presentation, and are presented solely to acquire a better understanding of Helix and may not be appropriate for other purposes nor should this presentation be redistributed to other parties. Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, orother circumstances change,except as required by law. Helix Corporate Presentation - - Sven Rohmann, MD, PhD, MBA 2
3 Company Brief Helix BioPharma Corp. ( Helix ) / Ticker symbol: HBP Est. 1996, clinical-stage, biopharmaceutical company Listed/trades on the Toronto Stock Exchange (TSX) and Frankfurt Stock Exchange (FSE) Shares outstanding: 89,959,279 Market Capitalization: CAD166.2M Share price: CAD week high-low: CAD CAD1.70 Backed by high net worth investors; No debt Raised CAD7.7M in 2016 Helix Corporate Presentation - - Sven Rohmann, MD, PhD, MBA 3
4 Management Team Sven Rohmann, MD, PhD, MBA: CEO Ø Experienced biotech entrepreneur, pharma manager (Merck, Novartis) and life science venture capitalist in the field of oncology (Burrill & Company, Adiuvo Investments) Frank Michalargias, CPA, CA: CFO Ø Public company CFO with broad industry experience including senior positions with Unilever and Huhtamaki Oy Heman Chao, PhD: CSO Ø Biochemist with expertise in protein drug development. Previous role with Sensium Technologies Inc. Steve Demas, BSc: CMO Ø Clinical operations experience with past roles at BioMS Medical, Bayer and Sanofi Synthelabo Patrick Frankham, PhD, MBA: COO Ø Biotech and pharma oncology drug development experience with past senior roles at Boehringer Ingelheim, ICON Clinical and AeternaZentaris Pawel Wisniewski, PhD: CEO Polska Ø Biochemistry background; co-founder Institute of Genetic Analysis Helix Corporate Presentation - - Sven Rohmann, MD, PhD, MBA 4
5 Development Product Pipeline As of August 2016 Preclinical Phase I Phase II Phase III Immunotherapy TIFN Topical BiPhasix interferon HPV Associated Cervical Intraepithelial Neoplasia (CIN) Tumor Defence Breaker L-DOS47 monotherapy NSCLC (ongoing) Tumor Defence Breaker Tumor Defence Breaker L-DOS47 Combination NSCLC (ongoing) L-DOS47 Combo Other Indications Tumor Defence Breaker Immuno Oncology Immuno Oncology Tumor Defence Breaker L-DOS47 Combo Immune Checkpoints CAR-T Solid Tumors (CEACAM6) CAR-T Hematologic Tumors (Bispecific) V-DOS47 Investigator initiated Helix Corporate Presentation - Sven Rohmann, MD, PhD, MBA 5
6 Helix TUMOR DEFENCE BREAKER is the next breakthrough in cancer therapy,.. Helix BioPharma holds the rights to two unique technology platforms: DOS47: which modifies the tumor microenvironment and stimulates the immune system against cancer cells (Tumor Defence Breaker ) CAR-T: which modifies genes and "arms" the immune system cells against cancer cells (Tumor Agent Attack) Their synergy can provide effective therapeutic solutions for patients with solid tumors. For thefirst time Curefrom Cancer appears possible. These platforms are protected by a family of patents with a global reach. October 2016 Helix BioPharma 6
7 thereby targeting the Oncology Hotspots The Global Oncology Market will reach revenues of $ 147 billion by 2018 IMS Health CAR-T Tumor Attack Agent Anticipated market size by 2024: > $ 20bn Anticipated market size by 2024: > $ 34bn Immuno-Onc. e.g. CHECKPOINT INHIBITORS DOS47 Tumor Defence Breaker CHEMOTHERAPY Year 2015 market size: > $ 56bn
8 Helix is focused on breaking the Tumor Defence October 2016 Helix BioPharma 8
9 Breaking the Tumor Defence - Rationale Source: Damaghi, M. et al. (2015). Nature Communications 6:8752 DOI: /ncomms Cancer cells can survive only in an acidic environment: Microenvironment of solid tumors is acidic (low ph) The low ph in tumors produces a number of clinically adverse effects: Accelerated growth of tumor cells Facilitating the formation of metastases Local immunosuppressive effect: "hibernation" of the most important cells of the immune system - T cells and NK cells (natural killers) Lack of satisfactory efficacy of conventional chemotherapeutic drugs and the latest immunological technologies (e.g. stimulating T cells and optimization of the so-called CAR T- cells) October 2016 Helix BioPharma 9
10 Acidosis blocks Checkpoint Inhibitors The acidic environment blocks the operation of the novel immunooncology drugs from the group of the so-called PD1/PDL1 inhibitors Tumor ph normalization enhances efficacy of check-point inhibitor in B16 melanoma model Cancer Res; 76(6) March 15, 2016 October 2016 Helix BioPharma 10
11 Acidity Impairs T-cell therapy Tumor ph normalization with adoptive T-cell transfer delays tumor growth (panel A) and provides survival advantage in a melanoma mouse model (panel B) Cancer Res; 76(6) March 15, 2016 Helix Corporate Presentation - - Sven Rohmann, MD, PhD, MBA 11
12 DOS47 The technology of TUMOR DEFENCE BREAKER DOS47 is a conjugate of urease with an antibody targeting a specific antigen only on the surface of tumor cells. Urease catalyzes the degradation of urea into ammonia and hydroxyl ions. DOS47 technology developed by Helix can lead to a radical destabilisation of tumor integrity by increasing the ph only of the tumor microenvironment. October 2016 Helix BioPharma 12
13 Tumor Defence Breaker - Countering Acidity Extends Survival In a breast cancer metastasis animal model, tumor ph normalization by systemic buffer therapy shows a significant reduction in size and number of metastases (Figure A and B). The survival of the animals is also extended (Figure B) "The acidic ph encountered in a tumor microenvironment has significant immunosuppressive effects. By neutralizing this acid, we were able to improve the response of melanoma and pancreatic tumors to immunotherapy," -- Robert J. Gillies, Ph.D., chair of the Department of Cancer Imaging and Metabolism at Moffitt. Cancer Res Mar 15; 69(6): Helix Corporate Presentation - - Sven Rohmann, MD, PhD, MBA 13
14 Tumor Defence Breaker - Clinical trials (LDOS001) L-DOS47 in combination treatment with conventional chemotherapeutic agents demonstrates very high anti-tumor efficacy in advanced (stage IV) lung cancer L-DOS47 in combination therapy with pemetrexed/carboplatin in patients with NSCLC (non small cell lung cancer) (first-line therapy in the US) No adverse effects in the group of 6 currently examined patients. Partial disappearance of tumor lesions in patients who received L-DOS47. Trial demonstrated 44% decrease of tumor diameters in combination therapy October 2016 Helix BioPharma 14
15 Tumor Defence Breaker - Clinical trials (LDOS002) L-DOS47 alone (monotherapy) shows antitumor efficacy in advanced (stage IV) lung cancer L-DOS47 was administered to six patients in the phase II clinical study 32 of 55 patients responded to the therapy in the phase I study showing: disease stabilization, no disease progress, and no new cancer lesions Trial demonstrated an overall 72% response rate to L-DOS47 October 2016 Helix BioPharma 15
16 TUMOR DEFENCE BREAKER - Clinical Program L-DOS47 NSCLC Phase II (Monotherapy) Phase I Readout - H2 2016, Phase II Readout H L-DOS47 Phase I/II (Immune checkpoint combo) First Patient In H L-DOS47 NSCLC Phase I (Combination Therapy US) Phase I Readout - H L-DOS47 NSCLC Phase II (Combination Therapy Europe) First Patient In - H L-DOS47 Other Indications Phase I/II (Combination Therapy) First Patient In - H CAR-T Phase I/II (Solid Tumors) First Patient In H Helix Corporate Presentation - - Sven Rohmann, MD, PhD, MBA 16
17 Cash Requirements Cash required - $33M (through to Jan 2018) Oct-2016 Jan-2017 Apr-2017 Jul-2017 Oct-2017 Jan-2018 Total to Jan2018 Admin - Corporate 903,247 1,175, , , ,066 1,161,756 5,835,770 R&D 1,348,034 1,299,721 1,633,710 1,353,654 1,211,943 1,197,254 8,044,316 IP 180,000 90,000 60,000 60,000 60,000 60, ,000 Fixed assets 255,800 27,500 2,500 2,500 2,500 2, ,300 Mftg/Stability 488, , , , , ,245 2,896,061 Clinical - LDOS001 - PhaseI 345, , , , , ,895 2,217,522 Clinical - LDOS002 - PhaseI 284, , ,483 Clinical - LDOS002 - PhaseII 578, , , , ,327,688 Clinical - LDOS003 - PhaseII 196,090 1,034, , ,338 1,022, ,338 4,930,279 Clinical - LDOS47 (investigator) - 1,375, , , , ,000 2,750,000 CAR-T , ,000 1,062,500 1,062,500 2,875,000 4,581,025 6,403,846 6,065,722 5,273,533 5,506,804 5,285,489 33,116,418 Helix Corporate Presentation - - Sven Rohmann, MD, PhD, MBA 17
18 Helix Use of the Proceeds The Helix BioPharma portfolio allows for a unique impact in the oncology market in a multi-billion dollar way Helix is completing Clinical Proof of Concept (PoC) Trials for the Therapy with the Tumor Defence Breaker. Helix will file an IND for its CAR-T Program within 12 months. Helix is targeting a US listing at the end of 2017 backed by positive data from the two technology platforms (comparable listed companies with one of the two Helix technologies are valued at $0.75-$2B) Helix Corporate Presentation - - Sven Rohmann, MD, PhD, MBA 18
19 Thank You Inquiries: CORPORATE FINANCE & IR Helix Corporate Presentation 19
Therapeutic Strategy Against Tumor Acidity Induced Immune- Suppression: L-DOS47 a Clinical Candidate for Lung Cancer.
Therapeutic Strategy Against Tumor Acidity Induced Immune- Suppression: L-DOS47 a Clinical Candidate for Lung Cancer June 2017 SACHS Forward-looking Statements This presentation document contains certain
More informationHelix BioPharma Corp. Jan 2018 Biotech Showcase
Helix BioPharma Corp Jan 2018 Biotech Showcase Forward-looking Statements This presentation document contains certain forward-looking statements and information (collectively, forwardlooking statements
More informationHelix BioPharma Corp. New Directions in Cancer Therapies
Helix BioPharma Corp. New Directions in Cancer Therapies Introduction Helix is a Canadian based biopharmaceutical company developing new drugs to treat cancer, using its platform pharmaceutical technologies.
More informationHelix BioPharma Corp.
Helix BioPharma Corp. New Directions in Cancer Therapy Investor Presentation September, 2012 Forward-Looking Statements This presentation document contains certain forward-looking statements and information
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationAGM Presentation For the year to 30 September February 2016
AGM Presentation For the year to 30 September 2015 25 February 2016 11 Forward Looking Statements This presentation includes forward-looking statements. These forward-looking statements involve known and
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationCompany overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationQ1 Results 2018 Webcast presentation 26 April 2018
Q1 Results 2018 Webcast presentation 26 April 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline,
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationCOMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing
COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationAnnual General Meeting TSX: IMV. May 1, Immunovaccine Inc. All rights reserved.
Annual General Meeting TSX: IMV May 1, 2018 2017 Immunovaccine Inc. All rights reserved. Forward-looking Statements Except for historical information, this presentation contains forward-looking statements,
More informationFirst self-administered antibody therapy for HIV in late-stage clinical trials. CytoDyn Annual Meeting of Stockholders August 24, 2017
First self-administered antibody therapy for HIV in late-stage clinical trials CytoDyn Annual Meeting of Stockholders August 24, 2017 (OTCQB: CYDY) www.cytodyn.com Forward-Looking Statements This presentation
More informationNOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX
Date: 14 August, 2018 Sydney, Australia ASX: NOX Noxopharm Limited NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ABN 50 608 966 123 Registered Office and Operations Office: Suite 3,
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationNeedham Healthcare Conference
UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES Needham Healthcare Conference March 2018 Safe Harbor This presentation contains forward-looking statements about Vaxart Inc. (f/k//a Aviragen Therapeutics,
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationAcasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C
Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C CaPre(R) Met All Primary and Key Secondary Endpoints Statistically
More informationCorporate Presentation
Corporate Presentation October 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine s current expectations
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationSavient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference EAST BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall
More informationTransCode Therapeutics, Inc All Rights Reserved
1 Disclaimers THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT ) OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationDISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL
DISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL Annual General Meeting 24 April 2018 Björn Frendéus, Acting CEO & CSO 1 IMMUNOTHERAPY HAS TRANSFORMED
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationTaiwan s Premier Biopharma and the future leader in Immuno-Oncology
1 Taiwan s Premier Biopharma and the future leader in Immuno-Oncology Safe Harbor Statement This presentation contains certain forwardlooking statements. These forward-looking statements may be identified
More informationNASDAQ: PBMD, ASX: PRR
NASDAQ: PBMD, ASX: PRR Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides
More informationCAELUM BIOSCIENCES. Corporate Overview May, 2017
CAELUM BIOSCIENCES Corporate Overview May, 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning
More informationCOMPANY PRESENTATION. Bernard Fortier, CEO
COMPANY PRESENTATION Bernard Fortier, CEO Forward Looking Statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationCelldex Provides Corporate Update and Reports First Quarter 2018 Results
May 10, 2018 Celldex Provides Corporate Update and Reports First Quarter 2018 Results HAMPTON, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationCorporate Presentation
Corporate Presentation November 27 th, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationCowen Annual Healthcare Conference. March 2018
Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationPresentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
More informationThe Tumor Microenvironment Company
The Tumor Microenvironment Company June 2018 Legal Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
More informationCorporate Update. NASDAQ: GALT April 9, 2018
Corporate Update April 9, 2018 NASDAQ: GALT www.galectintherapeutics.com Forward-Looking Statements This presentation contains, in addition to historical information, forward-looking statements within
More information